Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

• Status: Completed
• Trial end date: 2017-07-26
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Flecainide

Criteria

Inclusion Criteria:

• Suspect diagnosis of Brugada Syndrome or ARVC

• Idiopathic ventricular fibrillation and suspect concealed Brugada syndrome

• Family history of Brugada Syndrome

• Family history of unexpected cardiac sudden death

Exclusion Criteria:

• Type 1 Brugada Syndrome ECG

• Pregnancy

• History and/or evidence of ischemic cardiomyopathy

• Recent myocardial infarction

• Allergy or known adverse reaction to flecainide